Exploring the link between plasma sphingolipids and radiotherapy effectiveness in liver cancer
Official title: Correlation Between Plasma Sphingolipid Metabolites and the Efficacy of Radiotherapy in Hepatocellular Carcinoma
Run by Nanfang Hospital, Southern Medical University · NCT06864221 · Data updated 2026-11-12
This study is trying to see if the levels of certain fats in the blood can help predict how well radiotherapy works for people with liver cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 260 (estimated) |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | September 1, 2024 |
| Main results expected | January 1, 2026 |
| Study ends | June 1, 2026 |
| Registry record updated | March 12, 2025 |
| Trial ID | NCT06864221 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 80 years with a clinical diagnosis of primary liver cancer who are scheduled to undergo radiotherapy.
✕Probably not a fit
Patients with malignancies from other origins or those with severe uncontrolled comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the relationship between plasma sphingolipid levels and the efficacy of radiotherapy in patients with hepatocellular carcinoma. Utilizing advanced LC-MS/MS technology, the study aims to analyze the qualitative and quantitative aspects of sphingolipids in the plasma of liver cancer patients undergoing radiotherapy. By collecting clinical data related to patient prognosis, the research seeks to establish the significance of these metabolites as predictive biomarkers for treatment outcomes, potentially enhancing the effectiveness of radiotherapy in liver cancer management.
Why it matters
Potential benefit: If successful, this study could provide a new biomarker for predicting the effectiveness of radiotherapy in liver cancer patients, leading to more personalized treatment strategies.
How similar studies have gone: While the role of sphingolipid metabolism in radiation sensitivity is an emerging area, this specific approach has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients voluntarily signed the informed consent form. * Aged between 18 and 80 years. * Clinically diagnosed with primary liver cancer according to the latest treatment guidelines. * Determined by the treating physician to require radiotherapy. * Expected survival time of more than 3 months. Exclusion Criteria: * Patients who discontinued radiotherapy or did not complete the planned treatment. * Presence of malignancies from other origins. * Severe metabolic diseases such as uncontrolled diabetes, significant obesity, or fatty liver disease. * Uncontrolled comorbidities, such as severe cardiovascular or pulmonary diseases, that may affect treatment or study outcomes.
Where it's running
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Principal investigator: Yiyi Li, PhD — Nanfang Hospital, Southern Medical University
- Study coordinator: Yiyi Li, PhD
- Email: liiyiiyii@163.com
- Phone: +8613828486593
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases
This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.
-
Moderate-dose radiotherapy combined with Pembrolizumab for liver cancer with blood vessel blockage
This study is testing if combining a specific type of radiation therapy with the immunotherapy drug Pembrolizumab can help people with liver cancer that has blocked blood vessels feel better and live longer.
-
Adjuvant radiotherapy after liver surgery for liver cancer
This study is testing a new type of targeted radiation therapy after liver surgery to see if it helps people with liver cancer live longer and stay cancer-free.
-
Analysis of outcomes and side effects in patients receiving radiation therapy
This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.
-
How chronic liver diseases connect with other long-term illnesses
We will look back at hospital records to see if chronic liver diseases are linked with other systemic illnesses in adults who visited Tzu Chi gastroenterology clinics.
-
Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread
This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.